Iron in Congestive Heart Failure

NCT ID: NCT01837082

Last Updated: 2016-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis to be tested is whether treatment with intravenous iron (ferric carboxymaltose) will improve left-ventricular ejection fraction in patients with heart failure and iron deficiency as determined by cardiac magnetic resonance imaging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Iron Deficiency Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iron

ferric carboxymaltose

Group Type ACTIVE_COMPARATOR

ferric carboxymaltose

Intervention Type DRUG

Placebo

Sodium chloride 0.9%

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ferric carboxymaltose

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ferinject Sodium chloride 0.9%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Congestive heart failure
* At least 18 years of age
* Iron deficiency
* Dyspnea class II or III according to New York Heart Association
* Left-ventricular ejection fraction ≤ 45%

Exclusion Criteria

* Known sensitivity to any of the products to be administered during dosing
* Immediate need of transfusion
* Patients presenting with an active infection
* Thalassaemia
* Other forms of microcytic anemia not caused by iron deficiency
* History of acquired iron overload
* Need for revascularization, ST-segment elevation myocardial infarction or Non-ST-segment elevation myocardial infarction during the past 3 months (at time of randomization)
* Women who are pregnant or of childbearing age and not using medically acceptable effective contraception
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

RWTH Aachen University

OTHER

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role collaborator

University of Ulm

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Mahir Karakas

Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mahir Karakas, MD

Role: PRINCIPAL_INVESTIGATOR

University of Ulm

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Aachen

Aachen, , Germany

Site Status

University Heart Center Hamburg

Hamburg, , Germany

Site Status

University of Ulm

Ulm, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-001134-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

iCHF_D.3874

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TRICuspid Intervention in Heart Failure Trial
NCT04634266 ACTIVE_NOT_RECRUITING NA
INcrease Of VAgal TonE in CHF
NCT01303718 TERMINATED PHASE3